Drugs / GEN6050X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06392724 | Jul 2024 → Dec 2025 overdue | Duchenne muscular dystrophy | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN6050X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392724 ↗ |
| Route | Intravenous | “GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.” NCT06392724 ↗ |
| Target | DMD | “GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.” NCT06392724 ↗ |